Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantSI
Samos Investments
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
Samos Investments is the investment firm named in Electric Twin and Shennon financing histories.
Recorded funding activity
Electric Twin simulates audience behavior using synthetic models. Shennon develops targeted cancer immunotherapies. These are distinct research and biological products under one firm-level attribution.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12M 1 disclosed · full round size, not this investor’s share